Subacute Thyroiditis and Heart Failure in a Patient Presenting With COVID-19

Sherin Elsa Mathews, MD1,2, Jessica Castellanos-Diaz, MD1,2, Ashok Srihari, MD1,2, Sushma Kadiyala, MD1,2, Julio Leey-Casella, MD1,2, Hans K. Ghayee, DO1,2, and Amie Ogunsakin, MD1,2

Abstract
A 67-year-old male was admitted with shortness of breath and diarrhea. His COVID-19 polymerase chain reaction test was positive, and he was found to be in acute heart failure. Troponin levels were elevated, echocardiogram showed ejection fraction of 24%, and his electrocardiogram was normal. Inflammatory markers were elevated. Further testing revealed suppressed thyroid-stimulating hormone and elevated free thyroxine (T4). Differential diagnosis at this point included possible myocarditis from the viral illness, exacerbation of heart failure from the viral infection or from thyrotoxicosis was considered. Patient’s heart failure improved with initiation of heart failure therapies; however, biochemically, his thyroid function tests (TFTs) did not improve, despite empiric methimazole. Thyroid antibody tests were unremarkable. Thyroid ultrasound showed mildly enlarged thyroid gland with no increased vascularity and 5-mm bilateral cysts. Thyroid dysfunction was attributed to subacute thyroiditis from COVID-19, methimazole was tapered, and prednisone was initiated. The patient’s TFTs improved. With the ongoing COVID-19 pandemic, it is imperative that clinicians keep a broad differential in individuals presenting with heart failure, and obtaining baseline TFTs may be reasonable. Rapid treatment of the underlying thyroiditis is important in these patients to improve the cardiovascular outcomes. In our experience, steroid therapy showed a rapid improvement in the TFTs.

Keywords
COVID-19, subacute thyroiditis, prednisone

Introduction
The world has seen an emergence of a novel coronavirus disease 2019 (COVID-19), which has led to a global pandemic causing numerous hospitalizations and deaths. Healthcare systems have grappled with varied manifestations of the disease ranging from asymptomatic presentation to mild viral pneumonia and to those presenting with acute respiratory distress syndrome, stroke, and myocardial infarction. The pathogenesis of the disease involves entry of the virus through the respiratory system using the angiotensin-converting enzyme 2 (ACE2) as a receptor.1 Current data indicate that the major cause of acute respiratory distress syndrome and multi-organ failure is due to the overproduction of inflammatory markers resulting in a cytokine storm.2 Endocrine systems have also been affected by the virus through unknown mechanisms. Thyroid dysfunction has been seen in these patients with some presenting with nonthyroidal illness syndrome to others presenting with thyrotoxicosis from subacute thyroiditis. mRNA encoding for ACE2 receptors have also been identified in thyroid tissue samples, making them a potential target for inflammation.3–5 In this article, we present a case of a 67-year-old male who presented with COVID-19-induced subacute thyroiditis and heart failure.

1Malcom Randall veteran hospital, Gainesville, FL, USA
2University of Florida, Gainesville, FL, USA

Received January 18, 2021. Revised March 16, 2021. Accepted March 18, 2021.

Corresponding Author:
Amie Ogunsakin, MD, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Malcom Randall Veteran Hospital, 1600 SW Archer Road, Gainesville, FL 32608, USA.
Email: amie.ogunsakin@medicine.ufl.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Case Report

A 67-year-old male with a past medical history of chronic systolic and diastolic heart failure, coronary artery disease, diabetes mellitus type 2, chronic kidney disease, and atrial fibrillation was admitted with shortness of breath and diarrhea. Chest X-ray showed bilateral infiltrates. N-terminal pro B-type natriuretic peptide (NT-proBNP) was elevated at 24591 pg/mL (<350 pg/mL). Troponin was high at 0.15 ng/mL (0.3-0.10). Electrocardiogram did not show any ST-segment changes. C-reactive protein (CRP) level, 5.3 mg/dL (0.1-0.4 mg/dL), and erythrocyte sedimentation rate (ESR) level 37 mg/dL (0-15 mg/dL) were both elevated. Echocardiogram showed left ventricular ejection fraction of 24%.

The patient’s COVID-19 polymerase chain reaction testing was positive. Patient was started on ceftriaxone and azithromycin for pneumonia, and intravenous diuretics for heart failure. He had acute onset of atrial fibrillation for a brief duration, with spontaneous return to regular rate and rhythm.

Thyroid function tests (TFTs) obtained for further evaluation of arrhythmia showed a low thyroid-stimulating hormone (TSH) of 0.029 uIU/mL (0.27-4.2 uIU/mL) and elevated free thyroxine (T4) of 2.1 ng/dL (0.8-1.7 ng/dL; Table 1). He had no neck pain or preexisting diagnosis of hyperthyroidism. There was no history of biotin, levothyroxine, or amiodarone use. Patient had symptoms of weight loss, fatigue, and diarrhea. His thyroid examination was normal, and he had no proptosis. It was initially unclear if the patient may have had early Graves’ disease, toxic nodule, or thyroiditis. The patient was started on methimazole 20 mg daily, and thyroid autoantibody testing was obtained.

TFTs did not improve, and evaluation 4 weeks after initiation of methimazole showed elevated free T4 levels of 2.36 ng/dL (0.8-1.7 ng/dL) and undetectable TSH. Thyroid-stimulating antibodies, thyroid peroxidase antibody, thyroglobulin antibody level, and thyroid receptor antibody levels were normal. Thyroid ultrasound showed mildly enlarged thyroid gland with no increased vascularity and 5-mm bilateral cysts.

At this point, he was presumed to have to subacute thyroiditis from COVID-19. He was started on prednisone, and methimazole was tapered. Within a week, patient’s free T4 decreased to 1.36 ng/dL (0.8-1.7 ng/dL), and TSH then became detectable at 0.007 uIU/mL (0.27-4.2 uIU/mL) (Figure 1). Initially methimazole and then prednisone was slowly tapered over months. Patient is currently off methimazole and prednisone. His most recent TFT shows TSH of 1.05 uIU/mL (0.27-4.2 uIU/mL) and free T4 of 1.1 ng/dL (0.8-1.7 ng/dL). Patient is clinically asymptomatic, and we are closely watching his TFTs.

Discussion

On initial presentation, the patient had acute on chronic systolic heart failure. There was a preexisting history of chronic systolic congestive heart failure, which was likely exacerbated by COVID-19-induced thyroiditis. Myocarditis is also a differential diagnosis due to similarities in the clinical presentation. The clinical features of myocarditis may vary from subclinical disease to overt presentation of chest pain, heart failure, arrhythmias, and cardiogenic shock. The major causative agents in myocarditis are infectious causes, viral infections being a predominant factor.7

Subacute thyroiditis is a self-limited inflammatory disorder of the thyroid gland. The most common etiology of subacute thyroiditis is due to inflammatory process by viral infection.

A strong association with HLA-B35 antigen has been noted, with a higher predilection in females.8,9 The association of subacute thyroiditis with viral infections was noted back in the 1930s to 1940s, with measles, malaria, and scarlet fever.10-12 Direct evidence of the virus in the thyroid tissue has been seen in patients infected with mumps and retrovirus.13 It is interesting to note that previous epidemics with mumps have seen outbreaks of small clusters of subacute thyroiditis,14 and the outbreak of SARS in 2002-2003 also reported thyroid dysfunction.15 Classic symptoms of subacute thyroiditis include acute neck pain, tender thyromegaly, and thyrotoxicosis. TFTs show elevated free T4 levels with suppressed TSH response.16 Inflammatory markers are usually elevated.17 In situations when the diagnosis is in doubt, imaging studies such as radioactive iodine uptake and thyroid ultrasound can be helpful. Radioactive iodine uptake would show low activity. Thyroid ultrasound may show focal or diffuse heterogeneous/hypoechogenic areas, and the size of the thyroid gland would be usually normal. However, there are patients diagnosed with subacute thyroiditis who do have an enlarged thyroid gland on ultrasound.18 Thyroglobulin antibodies and thyroid peroxidase antibodies have been seen in some cases of subacute thyroiditis, but it is generally absent.19 In our case, the patient had suppressed TSH, with elevated free T4 levels and elevated markers of inflammation. Due to COVID-19 contact and droplet precautions, a radioactive iodine uptake scan was not performed. Therapy for subacute thyroiditis largely involves symptomatic measures and prednisone. Our patient improved with prednisone treatment.

COVID-19-induced thyroiditis and thyrotoxicosis cases are increasing20-28 and COVID-19-induced myocarditis has already been recognized as the cause of death in many cases.29,30 As such, it is important for physicians to have a broader differential in mind when evaluating cases presenting with heart failure in the setting of COVID-19.
## Table 1. Treatment and Laboratory Values.

| Date           | TSH (0.27-4.2 uU/mL) | Free T4 (0.8-1.7 ng/dL) | Total T3 (0.8-2 ng/mL) | TSI (< 140) | ESR (0-15 mg/dL) | CRP (0.1-0.4 mg/dL) | Treatment                  |
|----------------|----------------------|-------------------------|------------------------|-------------|-----------------|---------------------|--------------------------|
| March 24, 2020 | 0.029                | 2.1                     | 107                    |             |                 |                     |                          |
| April 1, 2020  |                      |                         |                        |             |                 |                     |                          |
| April 2, 2020  |                      |                         |                        |             |                 |                     |                          |
| April 3, 2020  |                      |                         |                        |             |                 |                     |                          |
| April 23, 2020 | 2.37                 | 1.21                    |                        |             |                 |                     |                          |
| April 25, 2020 | <0.005               | 2.71                    |                        |             |                 |                     |                          |
| April 27, 2020 | 2.57                 | 1.41                    |                        |             |                 |                     |                          |
| April 29, 2020 | 2.44                 | 1.40                    |                        |             |                 |                     |                          |
| May 26, 2020   | <0.005               | 2.36                    | 1.07                   |             |                 |                     | Prednisone 20 mg daily started |
| July 24, 2020  | 0.012                | 1.89                    |                        |             |                 |                     | Prednisone 20 mg daily, methimazole 10 mg daily |
| October 10, 2020 | 0.192              | 1.15                    |                        |             |                 |                     | Prednisone 15 mg daily, methimazole 5 mg daily |
| December 28, 2020 | 1.48              | 1.1                     |                        |             |                 |                     | Prednisone 5 mg daily, methimazole 2.5 mg daily |
| January 15, 2021 | 1.77               | 1.3                     |                        |             |                 |                     | Prednisone 5 mg daily and off methimazole |
| March 1, 2021  | 1.05                 | 1.1                     |                        |             |                 |                     | Off prednisone |

Abbreviations: TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine; TSI, thyroid-stimulating immunoglobulin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; bid, twice daily.
Conclusion

With the ongoing COVID-19 pandemic, it is imperative that clinicians keep a broad differential in individuals presenting with heart failure, and obtaining baseline TFTs may be reasonable. Rapid treatment of the underlying thyroiditis is important in these patients to improve cardiovascular outcomes. In our experience, steroid therapy showed a rapid improvement in the TFTs when tackling a case with subacute thyroiditis.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from the patient for their anonymized information to be published in this case report.

ORCID iD

Sherin Elsa Mathews https://orcid.org/0000-0002-9904-8770

References

1. Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43:1027-1031.
2. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32.
3. Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. Published online October 6, 2020. doi:10.1007/s40618-020-01436-w
4. Croce L, Gangemi D, Ancona G, et al. The cytokine storm and thyroid hormone changes in COVID-19. J Endocrinol Invest. Published online February 9, 2021. doi:10.1007/s40618-021-01506-7
5. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. Published online November 25, 2020. doi:10.1007/s11154-020-09615-z
6. Gorini F, Bianchi F, Iervasi G. COVID-19 and thyroid: progress and prospects. Int J Environ Res Public Health. 2020;17:6630.
7. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526-1538.
8. Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J Clin Endocrinol Metab. 1995;80:3653-3656.
9. Fatourechi V, Aniszewski JP, Fatourechi GZE, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, Study. J Clin Endocrinol Metab. 2003;88:2100-2105.

Figure 1. Free thyroxine (T4) and thyroid-stimulating hormone (TSH) trend.
10. Candel S. Acute nonspecific thyroiditis following measles; report of a case. *U S Nav Med Bull*. 1946;46:1109-1113.
11. Sein M, Calcutta MB. Acute non-suppurative thyroiditis. *Lancet*. 1938;2:673.
12. Jensen DR. Acute thyroiditis complicating scarlet fever. *Am J Surg*. 1943;60:301-303.
13. Desailloud R, Hober D. Viruses and thyroiditis: an update. *Virol J*. 2009;6:5.
14. Eylan E, Zmucky R, Sheba C. Mumps virus and subacute thyroiditis; evidence of a causal association. *Lancet*. 1957;272:1062-1063.
15. Wei L, Sun S, Xu CH, et al. Pathology of the thyroid in severe acute respiratory syndrome. *Hum Pathol*. 2007;38:95-102.
16. Weihl AC, Daniels GH, Ridgway EC, Maloof F. Thyroid function tests during the early phase of subacute thyroiditis. *J Clin Endocrinol Metab*. 1977;44:1107-1114.
17. Pearce EN, Bogazzi F, Martino E, et al. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. *Thyroid*. 2003;13:643-648.
18. Park SY, Kim EK, Kim MJ, et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. *Korean J Radiol*. 2006;7:229-234.
19. Nishihara E, Amino N, Kudo T, et al. Moderate frequency of anti-thyroglobulin antibodies in the early phase of subacute thyroiditis. *Eur Thyroid J*. 2019;8:268-272.
20. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after Sars-COV-2 infection. *J Clin Endocrinol Metab*. 2020;105:e237336.
21. Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. *J Endocrinol Invest*. 2020;43:1171-1172.
22. Kalkan EA, Ates I. A case of subacute thyroiditis associated with COVID-19 infection. *J Endocrinol Invest*. 2020;43:1173-1174.
23. Mattar SAM, Koh SJQ, Chandran SR, Cherng BPZ. Subacute thyroiditis associated with COVID-19. *BMJ Case Rep*. 2020;13:e237336.
24. Chakraborty U, Ghosh S, Chandra A, Ray AK. Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity. *BMJ Case Rep*. 2020;13:e239953.
25. Brancatella A, Ricci D, Cappellani D, et al. Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? Insights from a case series. *J Clin Endocrinol Metab*. 2020;105:e23a537.
26. Ruggeri RM, Campennì A, Siracusa M, Frazzetto G, Gullo D. Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. *Hormones (Athens)*. 2021;20:219-221.
27. Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. *Eur J Endocrinol*. 2020;183:381-387.
28. Campos-Barrera E, Alvarez-Cisneros T, Davalos-Fuentes M. Subacute thyroiditis associated with COVID-19. *Case Rep Endocrinol*. 2020;2020:8891539.
29. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19–related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. *Heart Rhythm*. 2020;17:1463-1471.
30. Inciardi RM, Lupi L, Zacccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5:819-824.